| Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355 … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... The Lancet 396 (10265), 1817-1828, 2020 | 1478 | 2020 |
| Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer J Cortes, HS Rugo, DW Cescon, SA Im, MM Yusof, C Gallardo, O Lipatov, ... New England Journal of Medicine 387 (3), 217-226, 2022 | 670 | 2022 |
| Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer K Shitara, JA Ajani, M Moehler, M Garrido, C Gallardo, L Shen, ... Nature 603 (7903), 942-948, 2022 | 333 | 2022 |
| First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial LG Paz-Ares, SS Ramalingam, TE Ciuleanu, JS Lee, L Urban, RB Caro, ... Journal of Thoracic Oncology 17 (2), 289-308, 2022 | 273 | 2022 |
| KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab+ chemotherapy versus placebo+ chemotherapy for previously untreated locally recurrent inoperable or … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... Journal of Clinical Oncology 38 (15_suppl), 1000-1000, 2020 | 213 | 2020 |
| KEYNOTE-355 Investigators Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative … J Cortes, DW Cescon, HS Rugo, Z Nowecki, SA Im, MM Yusof, C Gallardo, ... Lancet 396 (10265), 1817-1828, 2020 | 67 | 2020 |
| KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab+ chemotherapy vs placebo+ chemotherapy for metastatic TNBC HS Rugo, J Cortés, DW Cescon, S Im, MM Yusof, C Gallardo Ann Oncol 32 (suppl_5), S1283-S1346, 2021 | 61 | 2021 |
| First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial YY Janjigian, JA Ajani, M Moehler, L Shen, M Garrido, C Gallardo, ... Journal of Clinical Oncology 42 (17), 2012-2020, 2024 | 54 | 2024 |
| LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer … YY Janjigian, JA Ajani, M Moehler, M Garrido, C Gallardo, L Shen, ... Annals of Oncology 32, S1329-S1330, 2021 | 41 | 2021 |
| LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab+ chemotherapy vs placebo+ chemotherapy for metastatic TNBC J Cortés, DW Cescon, HS Rugo, SA Im, MM Yusof, C Gallardo, O Lipatov, ... Annals of Oncology 32, S1289-S1290, 2021 | 38 | 2021 |
| Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC … YY Janjigian, K Shitara, MH Moehler, M Garrido, C Gallardo, L Shen, ... Journal of Clinical Oncology 41 (16_suppl), 4025-4025, 2023 | 36 | 2023 |
| Nivolumab (NIVO) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC … K Shitara, YY Janjigian, MH Moehler, M Garrido, C Gallardo, L Shen, ... Journal of Clinical Oncology 40 (4_suppl), 240-240, 2022 | 24 | 2022 |
| Triple-negative breast cancer: the reality in Chile and in Latin America C Caglevic, J Anabalón, C Soza, E Milla, F Gaete, AM Carrasco, S Panay, ... ecancermedicalscience 13, 2019 | 20 | 2019 |
| Nivolumab (NIVO)+ chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC … E Elimova, K Shitara, MH Moehler, JA Ajani, L Shen, M Garrido, ... Journal of Clinical Oncology 42 (16_suppl), 4040-4040, 2024 | 19 | 2024 |
| Abstract GS3-01: additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for … HS Rugo, P Schmid, DW Cescon, Z Nowecki, SA Im, MM Yusof, ... Cancer Research 81 (4_Supplement), GS3-01-GS3-01, 2021 | 17 | 2021 |
| Testing of model-driven development applications B Marín, C Gallardo, D Quiroga, G Giachetti, E Serral Software Quality Journal 25, 407-435, 2017 | 17 | 2017 |
| Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: Impact on pathological complete … L Villanueva, J Anabalon, JM Butte, P Salman, S Panay, E Milla, ... ecancermedicalscience 15, 2021 | 13 | 2021 |
| 122MO Nivolumab (NIVO)+ ipilimumab (IPI) as first-line (1L) treatment (tx) for patients (pts) with advanced NSCLC (aNSCLC) and baseline (BL) brain metastases (mets … M Reck, TE Ciuleanu, A Pluzanski, JS Lee, RB Caro, H Linardou, ... Annals of Oncology 32, S1430-S1431, 2021 | 9 | 2021 |
| Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355 DW Cescon, P Schmid, HS Rugo, SA Im, M Md. Yusof, C Gallardo, ... JNCI: Journal of the National Cancer Institute 116 (5), 717-727, 2024 | 6 | 2024 |
| Abstract CT037: Nivolumab plus ipilimumab vs chemotherapy as first-line treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma … YY Janjigian, K Shitara, J Ajani, M Moehler, J Yao, L Shen, M Garrido, ... Cancer Research 83 (8_Supplement), CT037-CT037, 2023 | 6 | 2023 |
